Correction of leukocyte adhesion deficiency type II with oral fucose
- PMID: 10590041
Correction of leukocyte adhesion deficiency type II with oral fucose
Abstract
We describe a simple, noninvasive, and effective therapy for leukocyte adhesion deficiency type II (LAD II), a rare inherited disorder of fucose metabolism. This disorder leads to an immunodeficiency caused by the absence of carbohydrate-based selectin ligands on the surface of neutrophils as well as to severe psychomotor and mental retardation. The fucosylation defect in LAD II fibroblasts can be corrected by addition of L-fucose to the culture medium. This prompted us to initiate dietary fucose therapy on a patient with LAD II. Oral supplementation of fucose in this patient induced the expression of fucosylated selectin ligands on neutrophils and core fucosylation of serum glycoproteins. During 9 months of treatment, infections and fever disappeared, elevated neutrophil counts returned to normal, and psychomotor capabilities improved.
Comment in
-
Fucose supplementation in leukocyte adhesion deficiency type II.Blood. 2000 Jun 1;95(11):3641-3. Blood. 2000. PMID: 10877554 No abstract available.
Similar articles
-
Discontinuation of fucose therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte counts.Blood. 2001 Jan 1;97(1):330-2. doi: 10.1182/blood.v97.1.330. Blood. 2001. PMID: 11133780
-
Leukocyte adhesion deficiency II: therapy and genetic defect.Cells Tissues Organs. 2002;172(3):161-73. doi: 10.1159/000066968. Cells Tissues Organs. 2002. PMID: 12476046 Review.
-
Leukocyte Adhesion Deficiency Type II is a generalized defect of de novo GDP-fucose biosynthesis. Endothelial cell fucosylation is not required for neutrophil rolling on human nonlymphoid endothelium.J Clin Invest. 1998 Jun 1;101(11):2438-45. doi: 10.1172/JCI905. J Clin Invest. 1998. PMID: 9616215 Free PMC article.
-
Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene.Blood. 2003 Mar 1;101(5):1705-12. doi: 10.1182/blood-2002-09-2840. Epub 2002 Oct 24. Blood. 2003. PMID: 12406889
-
Leukocyte adhesion deficiency type II.Biochim Biophys Acta. 1999 Oct 8;1455(2-3):193-204. doi: 10.1016/s0925-4439(99)00071-x. Biochim Biophys Acta. 1999. PMID: 10571012 Review.
Cited by
-
Therapies and therapeutic approaches in Congenital Disorders of Glycosylation.Glycoconj J. 2013 Jan;30(1):77-84. doi: 10.1007/s10719-012-9447-5. Epub 2012 Sep 16. Glycoconj J. 2013. PMID: 22983739 Review.
-
Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature.J Clin Immunol. 2010 Mar;30(2):308-13. doi: 10.1007/s10875-009-9354-0. Epub 2010 Jan 23. J Clin Immunol. 2010. PMID: 20099014 Review.
-
Nutrition interventions in congenital disorders of glycosylation.Trends Mol Med. 2022 Jun;28(6):463-481. doi: 10.1016/j.molmed.2022.04.003. Epub 2022 May 10. Trends Mol Med. 2022. PMID: 35562242 Free PMC article. Review.
-
Genetics of glycosylation in mammalian development and disease.Nat Rev Genet. 2024 Oct;25(10):715-729. doi: 10.1038/s41576-024-00725-x. Epub 2024 May 9. Nat Rev Genet. 2024. PMID: 38724711 Review.
-
Nutritional Therapies in Congenital Disorders of Glycosylation (CDG).Nutrients. 2017 Nov 7;9(11):1222. doi: 10.3390/nu9111222. Nutrients. 2017. PMID: 29112118 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources